Celldex reports Q2 results; barzolvolimab Phase 3 data expected 2026
Celldex reported Q2 financial results, with Phase 3 enrollment for barzolvolimab in chronic spontaneous urticaria completed six months ahead of schedule.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day